Ribociclib + Ceritinib
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroblastoma
Conditions
Neuroblastoma, Cancer
Trial Timeline
Jul 1, 2016 → Aug 1, 2022
NCT ID
NCT02780128About Ribociclib + Ceritinib
Ribociclib + Ceritinib is a phase 1 stage product being developed by Novartis for Neuroblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02780128. Target conditions include Neuroblastoma, Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Neuroblastoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02780128 | Phase 1 | Terminated |
| NCT02292550 | Phase 1 | Completed |
Competing Products
20 competing products in Neuroblastoma